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Abstract
Background Fracture of the proximal femur is the most feared complication of osteoporosis. Given the numerous physi-
ological functions that magnesium performs in our body, in the literature there is a correlation between osteoporosis and 
low serum levels of magnesium.
Aim Evaluate the incidence of hypomagnesemia in patients with lateral fragility fracture of the proximal femur, the possible 
correlation between serum magnesium levels and fractures, and the effectiveness of supplementing  Sucrosomial® magnesium 
associated with therapeutic exercise on the outcome of these patients.
Methods We divided the study into two parts. In the first part, we assessed the preoperative incidence of hypomagnesemia 
in patients using a blood test. In the second part, patients with hypomagnesemia were divided, in the post-operative period, 
into two groups, who received, respectively, only therapeutic exercise or oral supplementation with sucrosomial magnesium 
associated with therapeutic exercise.
Results Half of the patients with fragility femoral fracture had hypomagnesemia, with a higher incidence of the subclinical 
form. From the comparison between the two groups, the T1 treatment group showed a significant improvement in blood 
levels of magnesium (2.11 ± 0.15 vs. 1.94 ± 0.11; p < 0.05), on the NRS scale (5.7 ± 0.81 vs. 6.6 ± 1.18; p < 0.05), the Tinetti 
scale (17.3 ± 1.15 vs. 15.2 ± 2.98; p < 0.05) and the SarQoL questionnaire (47.3 ± 5.21 vs. 44.9 ± 5.54; p < 0.05).
Conclusions More attention would be needed in the diagnosis and correction of subclinical hypomagnesemia and not just 
the simple and clinically evident one, including hypomagnesemia among the modifiable risk factors for osteoporosis.
Keywords Rehabilitation · Magnesium deficiency · Senile osteoporosis · Balance · Posture
Introduction
The fracture of the proximal portion of the femur is the most 
feared complication of osteoporosis.
Along with vertebral fractures, they are defined as brittle 
fractures, as they can occur as a result of low-energy trauma 
as a result of reduced bone mass and changes in bone struc-
ture [1].
This type of fracture accounts for 83% of hospitalization 
causes in osteoporotic patients. They are associated with 
high morbidity and mortality, in fact their mortality at 1 year 
is about 30% and at 5 years about 50% [2–4].
Given their high incidence, special attention should be 
paid to modifiable risk factors (cigarette smoking, alcohol, 
reduced body mass index (BMI), physical inactivity, and 
nutritional deficiencies).
It has been observed that nutritional deficiencies play an 
important role in the pathogenesis of osteoporosis [5, 6]. 
Bone metabolism is closely related to physical exercise and 
blood levels of calcium and vitamin D. An important role in 
bone metabolism is also played by some electrolytes, such as 
magnesium, and vitamins, like vitamin K. Their deficiency 
can have negative effects on the health of the bone, in fact 
now in the literature a correlation is known between osteo-
porosis and low serum levels of magnesium and/ or vitamin 
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K. Their integration seems to have a promising role in pre-
serving bone health [7, 8].
Magnesium plays an essential role in the physiologi-
cal functions of our organism (heart, brain, muscle, and 
skeleton) [9–11]. Its physiological range in a healthy adult 
is 20–28 g with a plasma concentration between 1.7 and 
2.6 mg/dl. Within the organism, 99% is present at the intra-
cellular level (60% in bones and 39% in muscles and soft 
tissues) and the remaining 1% in the extracellular environ-
ment [12]. The daily dietary intake of magnesium should 
reach 420 mg in men and 320 mg in women [9]. Magnesium 
homeostasis is closely related to the interaction between the 
intestine (responsible for the absorption of dietary magne-
sium), bone deposit, and urinary excretion [12]. Foods rich 
in magnesium include: nuts, seeds, fruit, vegetables, and 
whole grains [13].
Risk factors related to the onset of hypomagnesemia are: 
alcoholism, poorly controlled diabetes, malabsorption dis-
eases (e.g., Crohn’s disease and coeliac disease), chronic 
renal insufficiency and drug use (e.g. antibiotic, chemother-
apy, diuretics and proton pump inhibitors) [14].
Hypomagnesemia occurs mostly in the chronic subclini-
cal form with blurred or absent symptoms and plasma mag-
nesium concentrations in the standard [15]. Covers more 
than 70% of the population [16]. The subclinical form is 
defined as the presence of serum magnesium less than 
2.0 mg/dl, associated with urinary excretion within 24 h of 
40–80 mg/day. Free hypomagnesemia is defined by the pres-
ence of serum magnesium of less than 1.7 mg/dl [17].
In the case of hypomagnesemia, the ion is mobilized from 
the bone to restore its normal plasma concentration with 
reduced activity of osteoblasts and stimulation of osteoclas-
tic activity by the release of pro-inflammatory cytokines 
(TNF-alpha, IL-1, and substance P) which promote bone 
resorption [18].
Magnesium also influences serum parathormone (PTH) 
levels. Low serum magnesium levels result in paradoxical 
inhibition of PTH synthesis and secretion and resistance of 
peripheral tissues to the action of PTH since intracellular 
magnesium is a cofactor of adenylate-cyclase. This results 
in hypocalcemia which is not very responsive to treatment 
with calcium and vitamin D but is susceptible to correction 
with magnesium supplementation [7].
Also, magnesium is involved in maintaining the integrity 
of the endothelial wall, a fundamental component for bone 
nutrition [7].
Magnesium also acts at the muscle level serum magne-
sium levels are significantly associated with the risk of sar-
copenia in the elderly. It also intervenes in transmembrane 
transport, muscle contraction, and relaxation affecting mus-
cle performance. It is also involved in energy metabolism, 
affecting basic mitochondrial functions, including the syn-
thesis of ATP and the removal of reactive oxygen species. 
Poor availability of magnesium can lead to reduced mito-
chondrial efficiency and increased production of reactive 
oxygen species resulting in structural and functional dete-
rioration of proteins, DNA, and other essential molecules, 
in addition to a pro-inflammatory state [19].
In this study, we evaluated the incidence of hypomagnesia 
in patients with lateral fragility fracture of the proximal por-
tion of the femoral, the possible correlation between serum 
magnesium levels and fractures, and the effectiveness of 
 Sucrosomial® Magnesium supplementation associated with 
therapeutic exercise inpatients outcome.
Sucrosomial® Magnesium is an innovative oral prepara-
tion of magnesium oxide, covered by phospholipids plus 
sucrester matrix and can be used as an alternative to com-
mon magnesium salts to improve magnesium supplementa-
tion effectiveness. Through the encapsulation of magnesium 
ions within a sucrosomal membrane, they can cross the gas-
tric and intestinal environment and reach the bloodstream 
without interacting with the intestinal mucosa. All this 
allows increasing intestinal bioavailability and the bioavail-
ability of magnesium [20].
Materials and methods
An observational prospective study was conducted between 
April 2020 to February 2021 at the UOC of Rehabilitation 
of the Paolo Giaccone University Polyclinic in Palermo, in 
collaboration with the UOC of Orthopedics and Traumatol-
ogy of the same hospital.
The study was approved by the Medical Ethical Commit-
tee of the University Hospital of Palermo, Italy (n° 4/2020); 
written informed consent was obtained from each patient in 
conformity with Helsinki Declaration.
The Inclusion Criteria were: (1) age over 70; (2) diagno-
sis of lateral fracture by the fragility of the proximal portion 
of the femur.
Patients with altered states of consciousness, politrau-
matized, and subjects with medial fractures due to fragility 
of the proximal portion of the femur were excluded. Medial 
fractures have been excluded from the study as they can 
disrupt retinacolary vessels originating from the medial and 
lateral circumflex artery. The interruption of these vessels 
would involve the risk of avascular necrosis and pseudoar-
throsis that would require an osteosynthesis with prosthetic 
replacement of the head of the femur responsible in our 
opinion to invalidate the rehabilitation protocol, as well as 
that in turn, would need of longer patient recovery times.
The aim of the first part of the study was the evaluation 
of total magnesemia in these patients. For the determina-
tion of magnesemia, the cut-offs used were [17]: values 
below 1.7 mg/dl for free hypomagnesemia; values below 
2 mg/dl for subclinical hypomagnesemia; values above 
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2 mg/dl for normal magnesemia. Of 168 patients admit-
ted for lateral fracture from fragility, 75 patients were 
recruited that met all the criteria of inclusion. Of these 
only 36 patients had subclinical hypomagnesemia (n = 32) 
or frank hypomagnesemia (n = 4). Following a randomiza-
tion process to ensure equal distribution between the two 
groups (except for the 4 patients with free hypomagne-
semia included in the treatment group), we chose to divide 
patients with hypomagnesemia (subclinical or frank) into 
a first group called “treatment group”, composed of 17 
patients subjected to a rehabilitation protocol in associa-
tion with a magnesium supplement; and a second group, 
called “control group” composed of 19 patients who have 
undergone rehabilitation protocol only.
The rehabilitation protocol provided to these patients 
consisted of two phases. A first phase, defined as maximum 
protection, lasting 3 days was carried out immediately after 
surgery during the stay in the department of Orthopedics 
and Traumatology. The objectives of this phase were: rapid 
verticalization and prevention of bedside complications. A 
second phase, defined as controlled movement and minimum 
protection, was carried out under the DH regime at the UOC 
Rehabilitation, with a duration of 18 days. The goal was the 
general recovery of the locomotor system, stimulating the 
reactions of balance and posture to prevent the risk of a new 
fall, and the improvement of daily life activities (ADL). In 
this phase passive and active mobilization techniques were 
used, muscle pumping exercises, muscle strengthening exer-
cises, respiratory gymnastics, and exercises for the recovery 
of the correct pattern of pace and gait.
Patients in treatment group took a sachet of 
 Sucrosomial®Magnesium  (Ultramag®, Pharmanutra, Pisa, 
Italy) with a dosage of 375 mg of elemental magnesium, in 
oral suspension dissolved in a glasswater at room tempera-
ture, for 30 days, from the first day after surgery until the 
control visit, 1 month after the surgical intervention (T1).In 
addition, since all patients tested had a condition of insuf-
ficiency/deficiency of vitamin D [21] at the time of admis-
sion, they were also provided with an additional 25,000 UI 
cholecalciferol oral supplement once every 15 days from the 
first day after surgery to restore Vit D levels.
Patients were assessed at the basal, within 48 h of surgery 
(T0) and 1 month after the end of our rehabilitation proto-
col (T1) by: blood dosage of magnesium and vitamin Dand 
administration of assessment scales such as the NRS scale, 
the Tinetti test, and the Sarqol questionnaire.
The primary endpoint of the second part was to assess 
changes in serum levels of magnesemia in the two groups. 
The secondary endpoints were the evaluation oftolerability 
of  Sucrosomial® Magnesium, pain reduction, through the 
NRS scale, the reduction of the risk of new falls, through 
the Tinetti test, and the improvement of the quality of life, 
through the Sarqol questionnaire.
The Tinetti test, or Performance Oriented Mobility 
Assessment (POMA), is a clinical test commonly used to 
determine the equilibrium abilities of a subject, static and 
dynamic. It consists of two sections: the first examines the 
static balance in sitting and standing position, has 9 items, 
with a maximum score of 16 points; the second examines 
the gait, which has 7 items, with a maximum score of 12 
points. The maximum total score that can be obtained is 28 
points and based on the score obtained, three categories of 
patients can be distinguished: non-walker (0–1 score), risk 
of falls (2–20 score), and low risk of falls (score > 20) [22].
The Sarqolquestionnaire is a self-administrable psycho-
metric tool produced to estimate the quality of life in sub-
jects with sarcopenia and evaluate the changes in time in this 
population. It consists of 22 questions with 55 total items, 
specific for strength and muscle mass. The maximum score 
is 100 points, where the higher results reflect a better quality 
of life. Items are organized into seven domains: mental and 
physical health, locomotion, body composition, functional-
ity, ADL, pleasure, and fear activities [23].
The NRS scale is a quantitative assessment scale by 
which patients are asked to assess their pain on a defined 
scale, from 0 to 10, best reflecting the intensity of pain at 
that specific time [24].
Statistical analysis
Using the sample size estimation formula below,
Considering α = 0.05 and β = 0.10, we obtained a result 
of 39. Given the proximity between the theoretical sample 
size (equal to 39) and the actual sample size (equal to 36), 
we can conclude and assume that both the reliability val-
ues (1 − α = 0.95) and the power values (1 − β = 0.80) are 
respected. The data obtained were indexed on an Excel sheet 
and analyzed with the statistical software R. For the statisti-
cal modeling we used the classical linear regression model 
to evaluate the effect net of any confounding variables. p 
values < 0.05 were considered statistically significant. Pear-
son’s correlation index was then used to assess whether the 
variations were indeed proportional and how significant the 
association was.
Results
The general characteristics of the patients included in the 
study are given in Table 1. After an evaluation of 168 
patients admitted for lateral fracture from fragility, 75 
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inclusion criteria and were recruited. The average age was 
75 ± 2.5 years. 54.6% of the fractures (n = 41) involved the 
right femur, while the remaining 45.4% (n = 34) involved 
the left femur. At the time of the initial clinical evalua-
tion, patients reported an average NRS scale of 7.4–1.43. 
The most common anatomical site of the fracture, found 
in 49.3% of cases (n = 37) was the pertrocanteric region, 
and all received surgical treatment of osteosynthesis 
with endomedullary nail. More than half of the patients 
recruited (69.4%) had more than 3 comorbidities. At the 
time of admission, all the patients recruited showed a pic-
ture of vitamin D insufficiency/deficiency, with average 
values of 19.2 ± 7.43 ng/dl.
Mean serum magnesium values before the surgery (T0) 
were 1.92 ± 0.41. 52% (n = 39) had normal magnesemia 
values, while the remaining 48% (n = 36) had preoperative 
hypomagnesemia (Fig. 1). Of these 85% (n = 30 patients) 
had subclinical hypomagnesemia, while 15% (n = 6) had 
frank hypomagnesemia (Fig. 2).
The comparison of the anthropometric and clinical char-
acteristics at the base of the treatment and control groups is 
shown in detail in Table 2, where the homogeneity between 
the two groups is evident (p > 0.05).
Tables 3 and 4 show the trends of the variables ana-
lyzed in the control and treatment groups T0 to T1, 
respectively. In the control group, only the NRS scale 
showed significant improvements at T1 (7.5 ± 1.21 vs. 
6.2 ± 1.09; p < 0.05), while none of the variables consid-
ered showed significant changes at the end of the reha-
bilitation protocol consisting of functional rehabilita-
tion alone. On the contrary, in the treatment group we 
observed statistically significant changes in the magne-
semia values (1.86 ± 0.13 vs. 2.11 ± 0.15; p < 0.05), NRS 
scale (7.6 ± 0.93 vs. 5.7 ± 0.81; p < 0.05), Tinetti test 
(14.2 ± 3.24 vs. 17.3 ± 1.15; p < 0.05) and Sarqol ques-
tionnaire (42.4 ± 8,.23 vs. 47.3 ± 5.21; p < 0,05). No sta-
tistically significant change was reported for vitamin D 
values. In addition, no adverse events were reported and 
adherence to the treatment was maximum.
By applying a classical linear regression model we com-
pared the results obtained in patients in the treatment group 
with those of the control group (Table 5).
Comparing the treatment and control groups, we observed 
in the first a significant improvement in magnesaemia levels 
at T1 (2.11 ± 0.15 vs. 1.94 ± 0.41 mg/dl; p < 0.05) (Table 5), 
Table 1  General characteristicsat baseline of 75 patients
Characteristics
Anthtopometric characteristics





Weight, mean ± DS 74.3 ± 7.6





  NRS, mean ± DS 7.4 ± 1.43




Type of surgery, n° (%)




  ≥ 3 42 (69.4)
Vitamin D, mean ± DS 19.2 ± 7.43









Fig. 2  Prevalence of subclinical hypomagnesemia and frank 
hypomagnesemia in patients at baseline
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Table 2  Characteristics at 
baseline of treatment group and 
control group
Characteristics Treatment Group 
(N = 17)
Control Group (N = 19) p value
Anthropometric characteristics
 Age, mean ± SD 71.2 ± 3.1 72.8 ± 2.7 0.16
Gender, n° (%)
 Male 6 (35.3) 5 (26.3) 0.43
 Female 11 (64.7) 14 (73.7)
 Weight, mean ± DS 71.6 ± 4.6 74.2 ± 2.4 0.34
 BMI, mean ± DS 24.2 ± 3.7 23.8 ± 2.8 0.71
Clinical characteristics 0.28
 Laterality, n° (%)
  Right 7 (41.2) 11 (57.9)
  Left 10 (58.8) 8 (42.1)
  NRS, mean ± DS 7.6 ± 0,93 7.5 ± 1,21 0.79
 Anatomical site of the fracture n° (%) 0.56
  Pertrochanterics 10 (58.8) 12 (63.2)
  Intertrochanteric 2 (11.7) 1 (5.2)
  Subtrochanteric 5 (29.5) 6 (31.6)
 Type of surgery, n°(%) 0.62
  Intramedullary nail 13 (76.5) 12 (63.2)
  Plate and screws 4 (23.5) 7 (36.8)
 Comorbidity, n° (%) 0.44
  None 0 (0) 0 (0)
  1–2 3 (17.6) 5 (26.3)
   ≥ 3 14 (82.4) 14 (73.7)
Vitamin D, mean ± DS 17.7 ± 6.21 19.3 ± 5.41 0.41
Magnesemia levels, mean ± DS 1.86 ± 0,13 1.88 ± 0.21 0.73
Table 3  Effects of sucrosomal 
magnesium supplementation 
combined with therapeutic 
exercise in treatment group at 
T1
*Significant improvement
Characteristics T0 T1 p value
Magnesemia, mean ± DS 1.86 ± 0.13 2.11 ± 0.15  < 0.05*
Vitamin D, mean ± DS 17.7 ± 7.51 21.3 ± 6.83 0.14
NRS, mean ± DS 7.6 ± 0.93 5.7 ± 0.81  < 0.05*
Tinetti test, mean ± DS 14.2 ± 3.24 17.3 ± 1.15  < 0.05*
SarQoL, mean ± DS 42.4 ± 8.23 47.3 ± 5.21 0.05*
Table 4  Effects of only 
therapeutic exercise in the 
control group at T1
*Significant improvement
Characteristics T0 T1 p value
Magnesemia, mean ± DS 1.88 ± 0.21 1.94 ± 0,11 0.27
Vitamin D, mean ± DS 19.3 ± 5.41 21.7 ± 3.21 0.10
NRS, mean ± DS 7.5 ± 1.21 6.2 ± 1.09  < 0.05*
Tinetti test, mean ± DS 13.1 ± 4.52 15.2 ± 2.98 0.10
SarQoL, mean ± DS 44.6 ± 6.68 44.9 ± 5.54 0.88
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with percentage changes from baseline, 13.4% in the treat-
ment group and 3.2% in the control group.
Regarding the vitamin D values, no statistically signifi-
cant improvement was observed between the two groups 
(21.3 ± 6.83 vs. 21.7 ± 3.21; p = 0.82).
Analyzing the mean values of the NRS scale of both T1 
groups, we noticed a significant improvement in pain in the 
patients belonging to the treatment group compared to those 
of the control group (5.7 ± 0.81 vs. 6.2 ± 1.09; p < 0.05).
For Tinetti test score, at T1 the treatment group obtained 
an average score higher than the control group (17.3 ± 1.15 
vs. 15.2 ± 2.98; p = 0.001).
Finally, we also evaluated how the quality of life in rela-
tion to sarcopenia could vary after a month of integration 
with Sucrosomial®Magnesium. At T1, patients in the treat-
ment group had a higher Sarqol score than the control group 
which remained substantially unchanged (47.3 ± 5.21 vs. 
44.9 ± 5.54; p < 0.05).
By applying Pearson’s correlation we observed a moder-
ate correlation between magnesemia values and Tinetti test 
result (r = 0.506) and between magnesium values and NRS 
scale (r = 0.618). While a strong correlation was observed 
between magnesemia values and the result of the SarQoL 
questionnaire (r = 0.849).
Discussion
The fragility fracture of the proximal portion of the femur 
has an important clinical and economic impact on patients. 
It almost always requires hospitalization, in 20% of cases 
causes death, 50% of cases cause permanent disability and 
only 30% of cases heal completely [25, 26].
The first objective of this study was to assess the inci-
dence of subclinical hypomagnesemia in a cohort of geri-
atric patients with a lateral fracture from the fragility of the 
proximal portion of the femur and their possible correlation 
with serum magnesium levels.
We showed that hypomagnesemiais found in half of the 
patients suffering from femur fracture from fragility, with a 
greater incidence of the subclinical form. For this reason, it 
would be desirable to include it among the modifiable risk 
factors for osteoporosis.
This requires greater attention in the diagnosis and cor-
rection of subclinical hypomagnesemia and not only that 
frank, clinically evident.
The aim of the second part was to assess the effectiveness 
of magnesium supplementation the outcome of osteoporotic 
patients.
Our study highlights the safety of  Sucrosomial®Magnesium 
therapy demonstrated by adherence to treatment due to the 
absence of known side effects related to conventional magne-
sium (mainly gastrointestinal), single-dose formulation, and 
ease of intake.
In accord to our data, Brilli et al. [20] compared to the 
various magnesium formulations available on the market, 
the sucrosomial Magnesium formulation used, thanks to the 
presence of a phospholipid matrix around the magnesium 
ions, improves intestinal absorption of magnesium. Further-
more, this formulation, reaching the bloodstream directly 
without interacting with the intestinal mucosa, reduces the 
gastrointestinal side effects usually associated with Magne-
sium supplementation.
Another important point to highlight is that the correction 
of subclinical hypomagnesemia has positively influenced 
posture and balance as evidenced by the scale of Tinetti. 
Normally an unstable posture and altered pace pattern are 
both associated with an increased risk of falls and conse-
quently fractures and are often associated with sarcopenia 
[27]. At the end of the study protocol, patients who received 
Sucrosomial®Magnesium supplementation also showed an 
improvement in the score of the Sarqol questionnaire, espe-
cially in the mental and physical health domain. All this 
determines an improvement in the quality of life in relation 
to sarcopenia, as a consequence of the improvement in the 
functional capacity of the patients which led to their greater 
participation in daily life and recreational activities. The 
improvement of balance and strength is related to a reduc-
tion in the risk of falls and refractions.
However, in the past WHI studies have tried to analyze 
the possible relationship between magnesemia and the risk 
of falls. Although possible, the authors did not conclude for 
Table 5  Comparison of resultsat 
T1 between treatment group and 
control group
Characteristics Treatment group Control group p value 
(control vs. 
treatment)
Magnesemia, mean ± DS 2.11 ± 0.15 1.94 ± 0.11  < 0.05
Vitamin D, mean ± DS 21.3 ± 6.83 21.7 ± 3.21 0.82
NRS, mean ± DS 5.7 ± 0.81 6.2 ± 1.09 0.02
Tinetti test, mean ± DS 17.3 ± 1.15 15.2 ± 2.98 0.01
SarQoL, mean ± DS 47.3 ± 5.21 44.9 ± 5.54  < 0.05
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an observed possible direct correlation between magnesium 
and increased risk of falls probably. It has been hypothesized 
that the falls may be the result of the fact that women were 
more active and therefore have greater potential to fall and 
fracture [28].
The results obtained in the second part of the study should 
not be surprising, taking into account the extensive literature 
on the effects of magnesium and the increasing amount of 
evidence on the topic of subclinical hypomagnesemia.
Indeed, studies [9–16] have shown that the average die-
tary intake of magnesium of the European and North Ameri-
can population is lower than the recommended daily intake, 
exposing, in the long run, the risk of chronic magnesium 
deficiency.
The roles of magnesium in the determination of both sar-
copenia and osteopenia, as well as in various mitochondrial 
processes involved in the production of ATP are also evident 
[19–29].
The importance of magnesium in the muscles is under-
lined by the fact that one of the largest deposits of magne-
sium in our body is represented by the muscle [30]. Mag-
nesium, in addition to being involved in muscle metabolism 
processes, such as protein and ATP synthesis and the deg-
radation of glycogen, also influences muscle performance 
through energy metabolism, transmembrane transport, and 
muscle contraction and relaxation [19].
The role of magnesium as a modifiable risk factor for 
osteoporosis is now known, in consideration of the fact that 
low magnesium levels lead to reduced osteoblastic and oste-
oclastic activity, bone fragility, and strength or reduction of 
vitamin D and PTH [31, 32].
In the literature, substantial improvements in total body 
BMD have been shown following the intake of magnesium, 
describing a positive association [33]. In the Framingham 
Heart Study, a 2% higher trochanteric BMD has observed 
for every 100 mg of Mg consumed [34]. Further studies have 
shown an improvement in BMD or a reduction in markers of 
bone turnover following the intake of magnesium, however, 
the relationship with the outcome of the fracture was not 
clear [35].
Veronese et  al. have demonstrated that the intakeof 
300  mg/day of magnesium hydroxide has brought an 
improvement in the physical performance of treated sub-
jects, especially in terms of gait speed and chairs to stand 
test [36].
Our study is in line with this, in fact the results of 
the Sarqol questionnaire show a clear improvement in 
the functional capacity and participation of the patients 
examined.
An interesting fact highlighted by our study was the 
greater reduction of pain in patients undergoing the integra-
tion with Magnesium Sucrosomiale. Although this may be 
a result of several factors, including the therapeutic exercise 
that contributes to the control of pain, in the literature it is 
now known the role of Magnesium in the control of pain. 
Although it has no direct antinociceptive effects, it is con-
sidered a natural calcium antagonist. By inhibiting NMDA 
receptors, it blocks the entry of calcium ions into the cell, 
performing an analgesic effect and thus avoiding the devel-
opment of central sensitization and receptor hypersensitivity 
[37].
Our study further emphasizes the concept that osteo-
porosis is increasingly considered a condition of Sarco-
osteopenia, thus being able to define a pathology with two 
protagonists (sarcopenia and osteopenia) that, with the 
advancement of time and in the absence of a holistic and 
multidisciplinary approach, determines the so-called “spiral 
of fragility”. Magnesium, thanks to its dual and synergic 
role both on bone and muscle metabolism, is particularly 
suitable for this situation. It is therefore suggested to under-
line the importance of assessing the magnesium status and 
the correction of hypomagnesemia of elderly subjects, as 
it can improve their rehabilitation outcome. The correct 
dietary intake or direct supplementation of magnesium 
improves muscle strength as well as reducing the inci-
dence of symptoms such as myalgia and muscle cramps, 
resulting in greater compliance and a better rehabilitation 
result, especially in a critical moment such as the immediate 
post-operative.
Study limitations
The main limitations of our study were the small sam-
ple size, which does not allow us to generalize the results 
obtained and the inability to determine, even roughly, the 
average dietary intake of magnesium of individual patients. 
About this, the variations in magnesemia values could be 
the result not only of the integration practiced but also of a 
higher dietary intake arbitrarily taken by the patient.Another 
limitation, due to the low sample size, was that it did not 
stratify magnesemia levels and brittle fractures with other 
risk factors.
Possible suggestions for future studies could be a more 
precise analysis, for example through the dosage of carbox-
ylatedosteocalcin, of the effects of magnesium integration 
on osteogenesis in the post-fracture period. Again, it might 
be interesting to evaluate the organic status of magnesium 
with more specific analytical methods, such as the determi-
nation of the ionic form or intra-erythrocyte quantity, thus 
assessing the actual correlation with the total magnesemia 
parameter. Finally, it may be useful to evaluate, through 
the analysis of bone fragments taken during osteosynthesis/
prosthetization, the amount of cortical magnesium true res-
ervoir of this ion, compared to serum magnesemia, to shed 
light on more loyal subclinical hypomagnesemia suspect 
criteria.
 Aging Clinical and Experimental Research
1 3
Conclusion
The assessment of magnesemia, in elderly patients at risk of 
osteo-sarcopenia, should be carried out with routine humoral 
examinations and involve all specialists who treat the health 
of the elderly patient. Therefore, it would be desirable to 
measure magnesemia and correct any hypomagnesemia con-
ditions immediately, given the health benefit and low cost.
The results of our study, albeit obtained on a small sam-
ple, seem to demonstrate that magnesium supplementation 
positively influences posture and balance and improves 
the quality of life of subjects with frank or subclinical 
hypomagnesemia. In general, adding magnesium even to the 
habits of the healthy elderly population could improve bone 
and muscle metabolism, and consequently allow better reha-
bilitation results and reduce the risk of falls and fractions.
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